Product Description
BRM421 is a developing topical ophthalmic solution for patients with moderate-to-severe DES.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BRIM Biotechnology
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Taiwan, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07078955 |
BRM421-24-C001 | P2 |
Not yet recruiting |
Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes |
2026-11-01 |
12% |
2025-10-23 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
NCT05695781 |
BRM421-22-C001-PR | P3 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Disease|Dry Eye Syndromes |
2023-12-30 |
4% |
2024-07-12 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|